A Phase 3 interventional study of Oxycodone and Morphine in Cancer, sponsored by Mundipharma (China) Pharmaceutical Co. Ltd. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-05-21.
Sponsored by Mundipharma (China) Pharmaceutical Co. Ltd (part of Mundipharma) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The efficacy of dose titration of OxyNorm™(Oxycodone) immediate-release capsules versus morphine immediate-release tablets in the treatment of cancer pain.
To compare the efficacy of dose titration of OxyNorm™(Oxycodone) immediate-release capsules versus morphine immediate-release tablets in the treatment of cancer pain.
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 242 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Mundipharma (China) Pharmaceutical Co. Ltd is the lead sponsor of 19 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Oxycodone
Drug: Morphine
Numerical Rating Scale (NRS)
The numerical rating scale is the tool to assess pain level using a numerical rating scale. The primary outcome measurement is the average change of NRS score after double blind treatment between the two treatment groups. The NRS evaluates the pain level using number scale from 0 to 10. 0 means not painful and 10 means extremely painful. 1 to 3 is lightly pain, 4-6 is moderate pain and 7 to 10 is severe pain. There is no subscales used for NRS reporting.
Time frame: baseline up to 5-8 days (double blind period)
The Average Dose of Study Medicine Used During Double Blind Treatment Period
the average dose of study medicine used during double blind treatment period between the two treatment groups.
Time frame: baseline up to 5-8 days (double blind period)
Brief Pain Inventory (BPI) Change From Baseline to After Double Blind Period
The secondary outcome measurement is the change between BPI score at baseline and after completion of double blind treatment between the two treatment groups. The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning. This tool measures the worst/least pain in the passed 24 hours, and the average/current pain in last 24 hours. The scale is numerically from 0 to 10. 0 means not painful, 10 means extremely painful. The BPI is the average number of above 4 BPI Pain Items.
Time frame: baseline up to 5-8 days (double blind period)
Times of Breakthrough Pain Occurrence
the times of breakthrough pain occurrence during double blind treatment phase between the two treatment groups
Time frame: Within 8 days after baseline
Patient Assessments of Satisfaction for Pain Management
the number of patients of satisfaction for pain management between the two treatment groups at the end of double blind treatment and the open label treatment period.
Time frame: baseline up to 19-22 days (open label treatment)
Average Number of Titrations
the average times to change the dose in order to find the proper dose between two treatment groups
Time frame: baseline up to 1-3 days(double blind period)
Brief Pain Inventory (BPI) Change From Baseline to Open Label Treatment
The secondary outcome measurement is the change of BPI score from baseline to the end of open label treatment between the two treatment groups. The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning. This tool measures the worst/least pain in passed 24 hours, and the average/current pain in last 24 hours. The scale is numerically from 0 to 10. 0 means not painful, 10 means extremely painful. The BPI is the average number of above 4 BPI Pain Items.
Time frame: baseline up to 19-22 days (open label treatment)
the Total Dose of Rescue Medicine for Breakthrough Pain.
the total dose of rescue medicine for breakthrough pain during double blind phase between the two treatment groups
Time frame: baseline up to 22 days (double blind period)
Degree of Pain Relief Within 24hrs After Treatment
Brief Pain Inventory (BPI) Change From Baseline to After Double Blind Period. The BPI is the average number of above 4 BPI Pain Items. For the degree of pain relief within 24hrs after treatment, 0 means zero relief and 100 means completely relief with unit of percentage(%).
Time frame: baseline up to 5-8 days (double blind period)
Brief Pain Inventory (BPI) Change From Baseline to Open Label Treatment
For the degree of pain relief within 24hrs after treatment, 0 means zero relief and 100 means completely relief with unit of percentage(%).
Time frame: baseline up to 19-22 days (open label treatment)
A total of 242 subjects were enrolled from 20 centers in which 192 subjects completed the study and 50 subjects did not completed the study. All the subjects were recruited from medical clinic.The recruitment period is from 2011 Jan to 2012 Mar.
| Milestone | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain |
|---|---|---|
| Started | 122 | 120 |
| Completed | 96 | 96 |
| Not completed | 26 | 24 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Adverse event | 12 | 10 |
| Withdrew: Protocol violation | 4 | 1 |
| Withdrew: Lack of efficacy | 2 | 4 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Other | 5 | 4 |
The numerical rating scale is the tool to assess pain level using a numerical rating scale. The primary outcome measurement is the average change of NRS score after double blind treatment between the two treatment groups. The NRS evaluates the pain level using number scale from 0 to 10. 0 means not painful and 10 means extremely painful. 1 to 3 is lightly pain, 4-6 is moderate pain and 7 to 10 is severe pain. There is no subscales used for NRS reporting.
| scores on a scale | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain |
|---|---|---|
| Numerical Rating Scale (NRS) | 3.91 ± 2.31 | 3.87 ± 2.22 |
the average dose of study medicine used during double blind treatment period between the two treatment groups.
| mg | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain |
|---|---|---|
| Average total dosage during double-blind titration | 83.29 ± 82.87 | 141.61 ± 112.10 |
| Ave. total dosage during double-blind maintenance | 167.41 ± 103.92 | 308.63 ± 189.93 |
The secondary outcome measurement is the change between BPI score at baseline and after completion of double blind treatment between the two treatment groups. The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning. This tool measures the worst/least pain in the passed 24 hours, and the average/current pain in last 24 hours. The scale is numerically from 0 to 10. 0 means not painful, 10 means extremely painful. The BPI is the average number of above 4 BPI Pain Items.
| scores on a scale | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain |
|---|---|---|
| Highest pain intensity in 24 hrs | 4.25 ± 1.98 | 4.03 ± 2.20 |
| Lowest pain intensity in 24 hrs | 2.62 ± 2.08 | 2.53 ± 1.98 |
| Average pain intensity in 24 hrs | 3.39 ± 1.80 | 3.35 ± 1.73 |
| Current Pain intensity | 3.78 ± 1.94 | 3.70 ± 1.88 |
the times of breakthrough pain occurrence during double blind treatment phase between the two treatment groups
| breakthrough pain events | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain |
|---|---|---|
| Times of Breakthrough Pain Occurrence | 15 | 20 |
the number of patients of satisfaction for pain management between the two treatment groups at the end of double blind treatment and the open label treatment period.
| Participants | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain |
|---|---|---|
| Very satisfied | 35 | 37 |
| Satisfied | 64 | 61 |
| Neutral | 9 | 5 |
| Dissatisfied | 1 | 4 |
| Missing | 11 | 11 |
the average times to change the dose in order to find the proper dose between two treatment groups
| dose changes | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain |
|---|---|---|
| Average Number of Titrations | 8.25 ± 4.52 | 7.89 ± 3.43 |
The secondary outcome measurement is the change of BPI score from baseline to the end of open label treatment between the two treatment groups. The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning. This tool measures the worst/least pain in passed 24 hours, and the average/current pain in last 24 hours. The scale is numerically from 0 to 10. 0 means not painful, 10 means extremely painful. The BPI is the average number of above 4 BPI Pain Items.
| scores on a scale | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain |
|---|---|---|
| Highest pain intensity in 24 hrs | 3.98 ± 2.09 | 3.95 ± 1.92 |
| Lowest pain intensity in 24 hrs | 2.57 ± 2.05 | 2.64 ± 1.98 |
| Average pain intensity in 24 hrs | 3.33 ± 1.83 | 3.48 ± 1.57 |
| Current Pain intensity | 3.62 ± 1.87 | 3.71 ± 1.57 |
the total dose of rescue medicine for breakthrough pain during double blind phase between the two treatment groups
| mg | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain |
|---|---|---|
| the total dose of rescue medicine -day1 | 10.63 ± 7.76 | 7.00 ± 4.83 |
| the total dose of rescue medicine -day2 | 10.00 ± 8.29 | 6.00 ± 2.07 |
| the total dose of rescue medicine-day3 | 10.63 ± 8.21 | 6.82 ± 2.52 |
| the total dose of rescue medicine-day4 | 20.00 ± 8.94 | 7.86 ± 3.93 |
| the total dose of rescue medicine-day5 | 11.00 ± 10.84 | 6.67 ± 4.08 |
| the total dose of rescue medicine -day6 | 0 ± 0 | 5.00 ± 0.00 |
| the total dose of rescue medicine after day6 | 5.00 ± 0 | 5.00 ± 0.00 |
Brief Pain Inventory (BPI) Change From Baseline to After Double Blind Period. The BPI is the average number of above 4 BPI Pain Items. For the degree of pain relief within 24hrs after treatment, 0 means zero relief and 100 means completely relief with unit of percentage(%).
| percentage of pain relief | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain |
|---|---|---|
| Degree of Pain Relief Within 24hrs After Treatment | 35.23 ± 28.27 | 34.19 ± 30.85 |
For the degree of pain relief within 24hrs after treatment, 0 means zero relief and 100 means completely relief with unit of percentage(%).
| percentage of pain relief | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain |
|---|---|---|
| Brief Pain Inventory (BPI) Change From Baseline to Open Label Treatment | 32.31 ± 30.80 | 31.64 ± 29.73 |
Collected over up to 36 days. Non-serious events are listed at a 0.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oxycodone Capsules for Cancer Pain | 2/120 (1.7%) | 4/120 (3.3%) | 76/120 (63.3%) |
| Morphine Tablets for Cancer Pain | 2/118 (1.7%) | 2/118 (1.7%) | 75/118 (63.6%) |
| Event | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain |
|---|---|---|
| Respiratory and circulatory failureRespiratory, thoracic and mediastinal disorders | 2/120 | 2/118 |
| ileusGastrointestinal disorders | 1/120 | 0/118 |
| Brain metastasesNervous system disorders | 1/120 | 0/118 |
| Event | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain |
|---|---|---|
| ConstipationGastrointestinal disorders | 38/120 | 43/118 |
| NauseaGastrointestinal disorders | 25/120 | 26/118 |
| VomitingGastrointestinal disorders | 25/120 | 24/118 |
| DizzinessNervous system disorders | 9/120 | 6/118 |
| FeverImmune system disorders | 8/120 | 4/118 |
| DrowsinessNervous system disorders | 8/120 | 4/118 |
| DysuriaRenal and urinary disorders | 3/120 | 6/118 |
| Loss of appetiteNervous system disorders | 5/120 | 3/118 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/120 | 4/118 |
| Pulmonary infectionRespiratory, thoracic and mediastinal disorders | 3/120 | 4/118 |
| Age, Continuous(years) | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain | Total |
|---|---|---|---|
| Mean | 56.62 ± 12.96 | 57.05 ± 12.07 | 56.83 ± 12.50 |
| Sex: Female, Male(Participants) | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain | Total |
|---|---|---|---|
| Female | 58 | 59 | 117 |
| Male | 62 | 59 | 121 |
| Race (NIH/OMB)(Participants) | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 119 | 117 | 236 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain | Total |
|---|---|---|---|
| China | 120 | 118 | 238 |
| height(centimeter) | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain | Total |
|---|---|---|---|
| Mean | 164.5 ± 7.45 | 164.99 ± 8.20 | 164.74 ± 7.82 |
| weight(kg) | Oxycodone Capsules for Cancer Pain | Morphine Tablets for Cancer Pain | Total |
|---|---|---|---|
| Mean | 58.64 ± 10.79 | 58.34 ± 11.01 | 58.49 ± 10.88 |
No study locations are listed for this record.
Ran from Jan 2011 to primary completion in Jun 2012, 17 months.
Results were first posted in May 2018, 5 years 11 months after primary completion.
Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 17 months is below that.
Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxycodone
Mundipharma (China) Pharmaceutical Co. Ltd →